Durable regression of primary cutaneous B-cell lymphoma following fever-inducing mistletoe treatment: Two case reports

Global Advances In Health and Medicine

Volumn 1, Issue 1, 2012, Pages 18-25

  Orange, Maurice ^a   Lace, Aija ^f   Fonseca, Maria P ^b   von Laue, Broder H ^c   Geider, Stefan ^d   Kienle, Gunver S ^e  

^a Ita Wegman Klinik   (Switzerland)

^b Emerson College   (United Kingdom)

^c Niefern Oeschelbronn   (Germany)

^d Camphill Medical Practice NHS   (United Kingdom)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

^f NONE

Author keywords

Cancer; Fever; Lymphoma; Mistletoe treatment; PCBCL; PCFCL; PCMZL; Primary cutaneous B cell lymphoma; Tumor

Indexed keywords

VISCUM ALBUM EXTRACT;

ALTERNATIVE MEDICINE; ARTICLE; B CELL LYMPHOMA; CANCER REGRESSION; CASE REPORT; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; LEG EDEMA; PHLEBITIS; PRIORITY JOURNAL; SKIN LYMPHOMA; VISCUM ALBUM;

EID: 84880918912     PISSN: 2164957X     EISSN: 21649561     Source Type: Journal    
DOI: 10.7453/gahmj.2012.1.1.006     Document Type: Article

References (48)

1. Wiemann B, Starnes CO. Coley's toxin, tumor necrosis factor and cancer research: a historical perspective. Pharmac Ther. 1994;64(3):529-64.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005 May 15;105(10):3768-85.
3. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009 May 21;113(21):5064-73.
4. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005 Nov;153(5):874-80.
5. Willemze R. Primary cutaneous B-cell lymphoma: classification and treatment. Curr Opin Oncol. 2006 Sep;18(5):425-31.
6. National Comprehensive Cancer Network. NCCN guidelines™ version 4.2011: primary cutaneous B-cell lymphoma. Fort Washington: National Comprehensive Cancer Network; 2011.
7. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008 Sep 1;112(5):1600-9.
8. Zhao XF, Reitz M, Chen QC, Stass S. Pathogenesis of early leukemia and lymphoma. Cancer Biomark. 2011; 9(1-6):341-74.
9. Magro CM, Porcu P, Ahmad N, Klinger D, Crowson AN, Nuovo G. Cutaneous immunocytoma: a clinical, histologic, and phenotypic study of 11 cases. App Immunohistochem Mol Morphol. 2004 Sep;12(3):216-24.
10. Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol. 2006 Jun;125 Suppl:S38-49.
11. Takino H, Li C, Hu S, et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. Mod Pathol. 2008 Dec;21(12):1517-26.
12. Hoover RN. Lymphoma risks in populations with altered immunity-a search for mechanism. Cancer Res. 1992 Oct 1;52(19 Suppl):5477s-8s.
13. Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk Lymphoma. 2006 May;47(5):865-69.
14. Dummer R, Eichmüller S, Gellrich S, et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010 Jun;18(6):1244-7.
15. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004 Nov 18;351(21):2159-69.
16. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade Non-Hodgkin's lymphomas. N Engl J Med. 1984 Dec 6;311(23):1471-5.
17. Wiernik PH. Spontanremissionen bei lymphomen. In: Heim ME, Schwarz R, editors. Spontanremissionen in der onkologie. Stuttgart/New York: Schattauer Verlag; 1998. p. 193-199
18. Molassiotis A, Fernandez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005 Apr;16(4):655-63.
19. Kienle GS, Kiene H. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen. Stuttgart, New York: Schattauer Verlag; 2003.
20. Büssing A, editor. Mistletoe: the genus Viscum. Amsterdam: Hardwood Academic Publishers; 2000.
21. Büssing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999 Jan-Feb;19(1A):23-8.
22. Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010 Jun;9(2):142-57.
23. Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecologic cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res. 2009 Jun 11;28:79.
24. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007 Mar 26;12(3):103-19.
25. Matthes H, Schad F, Buchwald D, Schenk G. Endoscopic ultrasound-guided fineneedle injection of Viscum album L. (mistletoe; Helixor M) in the therapy of primary inoperable pancreas cancer: a pilot study. Gastroenterology. 2005;128(4 Suppl 2):433, T 988.
26. Mabed M, El-Helw L, Shamaa S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer. 2004 Jan 12;90(1):65-9.
27. Orange M, Fonseca M, Lace A, von Laue HB, Geider S. Durable tumour responses following primary high dose induction with mistletoe extracts: Two case reports. Eur J Integr Med. 2010 Jun;2(2):63-9.
28. Kienle GS, Grugel R, Kiene H. Safety of higher dosages of Viscum album L. in animals and humans-systematic review of immune changes and safety parameters. BMC Complement Altern Med. 2011 Aug 28;11:72.
29. Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. 2009 Jun;10(6):550-8.
30. Kuehn JJ. Treatment responses to viscum album pini (Iscador P) in non-Hodgkińs lymphoma exploring a new therapeutic route. Medicina (B Aires). 2007; 67(Suppl II):107-14.
31. Stumpf C, Rosenberger A, Rieger S, Tröger W, Schietzel M. [Mistletoe extracts in the therapy of malignant, hematological and lymphatic diseases-a monocentric, retrospective analysis over 16 years]. Forsch Komplementarmed Klass Naturheilkd. 2000 Jun;7(3):139-46. German.
32. Wagner R. Eine Praxisbeobachtung 1993 - 1996. Iscador-Informationen, Verein für Krebsforschung e V. Ostfildern. 1996;(4):1-42.
33. Wolf P. Die mistel-infusionstherapie zur behandlung von tumorleiden. Naturamed. 1989;4:720-724.
34. Goyert A. Niedrig dosierte Misteltherapie bei niedrig malignem Non-Hodgkin-Lymphom. Erfahrungsbericht. In: Scheer R, Becker H, Berg PA, editors. Grundlagen der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Stuttgart: Hippokrates Verlag GmbH; 1996. p. 362-5.
35. Kuehn JJ. [Favorable long-term outcome with mistletoe therapy in a patient with centroblastic-centrocytic non-Hodgkin lymphoma]. Dtsch Med Wochenschr. 1999 Nov 26;124(47):1414-8. German.
36. Kameda G, Kempf W, Oschlies I, Michael K, Seifert G, Längler A. [Nodal anaplastic large-cell lymphoma ALK-1- with CD30+ cutaneous lymphoproliferation treated with mistletoe: spontaneous remission or treatment response?] Klin Padiatr. 2011 Nov;223(6):364-7. German.
37. Seifert G, Tautz C, Seeger K, Henze G, Laengler A. Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/lymphomatoid papulosis. J Eur Acad Dermatol Venereol. 2007 Apr;21(4):558-60.
38. Kovacs E, Link S, Toffol-Schmidt U. Comparison of Viscum album QuFrF extract with vincristine in an in vitro model of human B-cell lymphoma WSU-1. Arzneimittelforschung. 2008;58(11):592-7.
39. Kuttan G, Vasudevan DM, Kuttan R. Effect of a preparation from Viscum album on tumor development in vitro and in mice. J Ethnopharmacol. 1990 Apr;29(1):35-41.
40. Braun JM, Ko HL, Schierholz JM, Weir D, Blackwell CC, Beuth J. Application of standardized mistletoe extracts augment immune response and down regulates metastatic organ colonization in murine models. Cancer Lett. 2001 Sep 10;170(1):25-31.
41. Kuttan G, Vasudevan DM, Kuttan R. Tumour reducing activity of an isolated active ingredient from mistletoe extract and its possible mechanism of action. J Exp Clin Cancer Res. 1992;11(1):7-12.
42. Pryme IF, Bardocz S, Pusztai A, Ewen SW. Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma. Histol Histopathol. 2002 Jan;17(1):261-71.
43. Frantz M, Jung ML, Ribéreau-Gayon G, Anton R. Modulation of mistletoe (Viscum album L.) lectins cytotoxicity by carbohydrates and serum glycoproteins. Arzneimittelforschung. 2000 May;50(5):471-8.
44. Stettin A, Schultze JL, Stechemesser E, Berg PA. Anti-mistletoe lektin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr. 1990 Sep 14;68(18):896-900.
45. Kienle GS. Fever in cancer treatment: Coley's therapy and epidemiologic observations. Global Adv Health Med. 2012;1(1):92-100.
46. Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin's lymphoma. Cancer. 1980 May 15;45(10):2627-32.
47. Papac RJ. Spontaneous regression of cancer. Cancer Treat Rev. 1996 Nov;22(6):395-423.
48. Bekkenk MW, Vermeer MH, Geerts ML, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol. 1999 Aug;17(8):2471-8.